Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04749368




Registration number
NCT04749368
Ethics application status
Date submitted
7/02/2021
Date registered
11/02/2021
Date last updated
18/06/2024

Titles & IDs
Public title
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Scientific title
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
Secondary ID [1] 0 0
BRII-179-835-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis B, Chronic 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BRII-835 (VIR-2218)
Treatment: Other - BRII-179 (VBI-2601) with IFN-a
Treatment: Other - BRII-179 (VBI-2601)

Experimental: Cohort A - Participants will receive BRII-835 (VIR-2218) for 32 weeks

Experimental: Cohort B - Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-a up to Week 40

Experimental: Cohort C - Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40


Treatment: Drugs: BRII-835 (VIR-2218)
BRII-835 (VIR-2218) will be given by subcutaneous injection

Treatment: Other: BRII-179 (VBI-2601) with IFN-a
BRII-179 (VBI-2601) with IFN-a will be co-administered by intramuscular injection

Treatment: Other: BRII-179 (VBI-2601)
BRII-179 (VBI-2601) will be administered by intramuscular injection
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of participants with sustained HBsAg loss during the 48-week follow-up period after NrtI withdrawal
Timepoint [1] 0 0
up to Week 96
Primary outcome [2] 0 0
Number of participants with Adverse Events (AE)
Timepoint [2] 0 0
up to Week 96
Primary outcome [3] 0 0
Number of participants with Serious Adverse Events (SAE)
Timepoint [3] 0 0
up to Week 96
Primary outcome [4] 0 0
Number of participants with abnormalities in clinical laboratory tests
Timepoint [4] 0 0
up to Week 96

Eligibility
Key inclusion criteria
* Male or female aged 18 - 60
* Body mass index = 18 kg/m^2 and = 32 kg/m^2
* Chronic HBV infection as defined by a positive serum HBsAg for = 6 months
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
* Significant fibrosis or cirrhosis
* History or evidence of drug or alcohol abuse
* History of intolerance to SC or IM injection
* History of chronic liver disease from any cause other than chronic HBV infection
* History of hepatic decompensation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/07/2023
Sample size
Target
Accrual to date
Final
91
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Investigative Site 61002 - Kingswood
Recruitment hospital [2] 0 0
Investigative Site 61001 - Westmead
Recruitment hospital [3] 0 0
Investigative Site 61004 - Herston
Recruitment postcode(s) [1] 0 0
2747 - Kingswood
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment outside Australia
Country [1] 0 0
China
State/province [1] 0 0
Changhua, Taiwan
Country [2] 0 0
China
State/province [2] 0 0
Hongkong
Country [3] 0 0
China
State/province [3] 0 0
Kaohsiung, Taiwan
Country [4] 0 0
China
State/province [4] 0 0
NEW Territories, Hong Kong
Country [5] 0 0
China
State/province [5] 0 0
Taichung, Taiwan
Country [6] 0 0
China
State/province [6] 0 0
Taipei CITY
Country [7] 0 0
Korea, Republic of
State/province [7] 0 0
Busan
Country [8] 0 0
Korea, Republic of
State/province [8] 0 0
Seongnam-si, Gyeonggi-do
Country [9] 0 0
Korea, Republic of
State/province [9] 0 0
Seoul
Country [10] 0 0
New Zealand
State/province [10] 0 0
Dunedin
Country [11] 0 0
New Zealand
State/province [11] 0 0
Auckland
Country [12] 0 0
Singapore
State/province [12] 0 0
Singapore
Country [13] 0 0
Thailand
State/province [13] 0 0
Bangkok
Country [14] 0 0
Thailand
State/province [14] 0 0
Chiang Mai
Country [15] 0 0
Thailand
State/province [15] 0 0
Khon Kaen
Country [16] 0 0
Thailand
State/province [16] 0 0
Nonthaburi
Country [17] 0 0
Thailand
State/province [17] 0 0
Pathumthani
Country [18] 0 0
Thailand
State/province [18] 0 0
Songkhla

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Brii Biosciences Limited
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Vir Biotechnology, Inc.
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
VBI Vaccines Inc.
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Trial website
https://clinicaltrials.gov/study/NCT04749368
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Xiaofei Chen
Address 0 0
Brii Biosciences Limited
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04749368